Agomab Announces Results of Annual General Meeting
Agomab Therapeutics NV, a clinical-stage biopharmaceutical company listed on Nasdaq, announced at its Annual General Meeting on May 26, 2026, that all agenda items were approved, including approval of financial statements for 2025, discharge of board members and auditors, and reappointments to the Board of Directors. The company focuses on developi…